Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 72Lymphoma 63Lymphoma, Follicular 59Lymphoma, Mantle-Cell 58Lymphoma, Large B-Cell, Diffuse 40Multiple Myeloma 36Hodgkin Disease 32Recurrence 29Lymphoma, B-Cell, Marginal Zone 28Lymphoma, B-Cell 19Leukemia 18Waldenstrom Macroglobulinemia 14Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasms, Plasma Cell 8Lymphoma, T-Cell 7Leukemia, Myeloid, Acute 7Burkitt Lymphoma 7Lymphoma, T-Cell, Peripheral 6Leukemia, B-Cell 6Hematologic Neoplasms 6Sezary Syndrome 5Myelodysplastic Syndromes 5Mycosis Fungoides 5Immune System Diseases 5Small Cell Lung Carcinoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large-Cell, Anaplastic 4

Interventions

Cyclophosphamide 23blinatumomab 18Cytarabine 16fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Daunorubicin 7Mercaptopurine 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Drug Therapy 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm, Residual × Bendamustine Hydrochloride × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT03524235 2024-11-12

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Cedars-Sinai Medical Center

Phase 1 Completed
20 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡